Thetis cells, a class of immune cells first described in 2022, play an essential and previously unknown role in suppressing inflammatory responses to food, a new study finds.

Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

Patients in the US with newly diagnosed GCA face excessive delays to initiating subcutaneous TCZ, as well high out-of-pocket costs.

Actemra has possible interactions with some other drugs. Examples include atorvastatin and warfarin. Talk with your doctor to ...

A low-grade fever ranges from 99.5 F to 100.2 F. This article covers symptoms, causes, and home treatment for a mild fever.

DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology ...

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the first new approval for the condition since tocilizumab in 2017, according ...

The Food and Drug Administration (FDA) has approved Rinvoq ® (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with giant cell arteritis (GCA). The approval was based on data ...

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA). The approval follows the recent marketing ...

Plus, news about the No­vo Nordisk Foun­da­tion and Tonix: Ab­b­Vie’s Rin­voq gets la­bel ex­pan­sion: The block­buster JAK in­hibitor won ap­proval in … ...